KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EBITDA (2020 - 2025)

Ginkgo Bioworks Holdings' EBITDA history spans 6 years, with the latest figure at -$80.9 million for Q4 2025.

  • For Q4 2025, EBITDA rose 26.19% year-over-year to -$80.9 million; the TTM value through Dec 2025 reached -$309.1 million, up 43.83%, while the annual FY2025 figure was -$309.1 million, 43.83% up from the prior year.
  • EBITDA reached -$80.9 million in Q4 2025 per DNA's latest filing, down from -$80.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$26.7 million in Q3 2021 to a low of -$1.7 billion in Q4 2021.
  • Average EBITDA over 5 years is -$287.0 million, with a median of -$168.4 million recorded in 2022.
  • Peak YoY movement for EBITDA: plummeted 2914.48% in 2021, then soared 90.04% in 2022.
  • A 5-year view of EBITDA shows it stood at -$1.7 billion in 2021, then skyrocketed by 90.04% to -$167.8 million in 2022, then fell by 23.55% to -$207.3 million in 2023, then skyrocketed by 47.13% to -$109.6 million in 2024, then grew by 26.19% to -$80.9 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's EBITDA are -$80.9 million (Q4 2025), -$80.4 million (Q3 2025), and -$57.8 million (Q2 2025).